Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.43 |
| ▸ | S100A4 | P26447 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1068743 | 0.88 | SMN1; SMN2 (0.50) | ABCB1ABCC1S100A4TRPV1MAPT | |
| SCHEMBL27892308 | 0.86 | SMN1; SMN2 (0.49) | ABCB1ABCC1S100A4TRPV1MAPT | |
| SCHEMBL6885938 | 0.84 | PTGDR2 (0.35) | ABCB1ABCC1MAPTALDH1A1MEN1 | |
| SCHEMBL22321528 | 0.83 | ABCB1 (0.42) | ABCB1ABCC1S100A4TRPV1MAPT | |
| SCHEMBL11643870 | 0.81 | ABCB1 (0.44) | ABCB1ABCC1S100A4TRPV1MAPT | |
| SCHEMBL27714420 | 0.81 | VCP (0.46) | ABCB1ABCC1MAPTALDH1A1MEN1 | |
| SCHEMBL7674664 | 0.80 | ABCB1 (0.43) | ABCB1ABCC1S100A4TRPV1MAPT | |
| SCHEMBL4763859 | 0.79 | ABCB1 (0.43) | ABCB1ABCC1S100A4TRPV1MAPT | |
| SCHEMBL27661940 | 0.78 | TBXA2R (0.45) | ABCB1ABCC1MAPTALDH1A1MEN1 | |
| SCHEMBL5917477 | 0.78 | BCL9 (0.50) | ABCB1ABCC1MAPTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1003721-B1 | BENZYLIDENE-1,3-DIHYDRO-INDOL-2-ONE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS, PARTICULARLY OF RAF KINASES | GLAXO GROUP LTD (GB) | 2006-11-02 | — | — | EP | disclosed |
| EP-1263728-A2 | PDE IV INHIBITING AMIDES, COMPOSITIONS AND PHARMACEUTICAL USE | MERCK FROSST CANADA INC. (CA) | 2002-12-11 | — | — | EP | disclosed |
| US-6436965-B1 | INHIBITION OF PHOSPHODIESTERASE; 3-CARBOCYCLIC(ALKYL)OXY-2-ARYL(ALKYL)AMINOCARBONYL-1-ARYL(ALKYL)INDOLE OR AZAINDOLE DERIVATIVES | MERCK FROSST CANADA & CO. (CA) | 2002-08-20 | — | — | US | disclosed |
| US-20020068756-A1 | PDE IV inhibiting amides, compositions and methods of treatment | MERCK FROSST CANADA LTD. (CA) | 2002-06-06 | — | — | US | disclosed |
| WO-2001064639-A2 | PDE IV INHIBITING AMIDES, COMPOSITIONS AND PHARMACEUTICAL USE | MERCK FROSST CANADA & CO. (CA) | 2001-09-07 | — | — | WO | disclosed |
| US-6268391-B1 | Benzylidene-1,3-dihydro-indol-2-one derivatives a receptor tyrosine kinase inhibitors, particularly of Raf kinases | GLAXO WELLCOME INC. | 2001-07-31 | — | — | US | disclosed |
| EP-1003721-A1 | BENZYLIDENE-1,3-DIHYDRO-INDOL-2-ONE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS, PARTICULARLY OF RAF KINASES | GLAXO GROUP LIMITED (GB) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999010325-A1 | BENZYLIDENE-1,3-DIHYDRO-INDOL-2-ONE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS, PARTICULARLY OF RAF KINASES | GLAXO GROUP LIMITED (GB) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068756-A1 | PDE IV inhibiting amides, compositions and methods of treatment | PDE3A, PDE3B, PDE4A | ABCB1 1430/4885ABCC1 1307/4885S100A4 3797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.